NCT07118176Active, not recruitingPhase 1
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 5 Aug 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 23 Jun 2026
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Prostate cancer, Thyroid cancer, Neuroendocrine tumours, Bladder cancer, Cervical cancer, Lung cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer, Ovarian cancer, Sarcoma
- NCT number
- NCT07118176
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- From 1 Aug 2025 to the primary completion date, 23 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data
Other
- Patient is pregnant or nursing
Who the study is looking for
- Patients with the following suspected or diagnosed cancer types:
- Adrenal cancer
- Anal cancer
- Bladder cancer
- Brain cancer
- Breast cancer
- Cancer of unknown primary (CUP)
- Cervical cancer
- Cholangiocarcinoma
- Colorectal cancer
- Esophageal cancer
- Gastric cancer
- Head and neck cancer
- Hematologic cancer
- Hepatocellular carcinoma
- Lung cancer
- Medullary thyroid cancer
- Neuroendocrine neoplasias
- Ovarian cancer
- Pancreatic cancer
- Penile cancer
- Peritoneal cancer
- Pleural cancer
- Prostate cancer
- Sarcoma
- Salivary gland cancer
- Solitary fibrous tumor
- Skin cancer
- Testicular cancer
- Thymus cancer
- Thyroid cancer
- Urothelial cancer
- Uterus cancer
- Vaginal cancer
- Patients are ≥ 18 years old at the time of the radiotracer administration
- Patient can provide written informed consent
- Patient is able to remain still for duration of imaging procedure (up to one hour)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.